ArticleHealth affairs scholar2026
A multi-stakeholder survey on communicating cost-effectiveness uncertainties to stakeholders: a case study of ICER.
Article in Health affairs scholar, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cost-effectiveness analyses (CEA) are integral to health technology assessments performed by the US-based Institute for Clinical and Economic Review (ICER). This study aims to examine how stakeholder groups perceive and interpret ICER's communication on uncertainty in CEA findings. Methods: We performed a multi-stakeholder survey among individuals recruited via ICER's weekly update email (March/April 2025). The survey focused on 6 topics related to ICER's uncertainty communication based on the organization's published reference case, consisting of Likert-scale and open-ended questions. Results were analyzed descriptively with thematic analysis of open-ended responses. Results: Thirty-four responses were collected, representing different stakeholder groups. Results indicated that 16/18 of respondents found sensitivity analyses to be communicated clearly (varying by analysis type), while 9/17 found structural and parametric assumptions to be communicated clearly. Most report sections were understandable respondents, and 15/23 found the communication of uncertainty outside reports to be understandable. Thematic analysis identified scenario analyses, structural/parametric uncertainty communication, and stakeholder-tailored communications as areas for future enhancement. Conclusions: While methodological guidelines focus on quantifying uncertainty, limited guidance exists for communicating key facts on uncertainty to different stakeholder groups. This study highlights specific stakeholder-perceived areas for improvement. Future research could compare these results to other organizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.